Catalyst
Slingshot members are tracking this event:
Aerie (AERI) Resubmits of New Drug Application for Glaucoma Treatment Rhopressa
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AERI |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 01, 2017
Occurred Source:
https://www.sec.gov/Archives/edgar/data/1337553/000119312517063823/d252074d8k.htm
Related Projects
- Getting a better understanding of the AERI Glaucoma program ahead of the Rhopressa NDA filing & Roclatan 90 day data in the 3rd quarter AERI, NVS, AGN Executed On: Aug 10, 2016 at 03:30 PM EDT
Related Keywords
New Drug Application, Fda, Rhopressa, Glaucoma, Resubmission
